Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First? D. Moreno-Ramírez, A. Fernández-Orland, L. Ferrándiz

Epidemiology of Melanoma in Spain: Estimation of Number of Patients With Stage III Disease Eligible for Adjuvant Therapies E. Nagore, D. Moreno-Ramírez, P. Ortiz-Romero, E. Martín-Sánchez, A. Martínez-Fernández, S. Puig

Real-World Evidence of Adjuvant Immunotherapy in Resected Stage III and IV Melanoma Patients: CADIM Trial Final Results. Experience From 2 Tertiary Referral Centers M. Morellá Fernández, J. Balsalobre Yago, J. Martínez García, M. Peláez Gutiérrez, A. López Muñoz, A.I. Silvestre Ballesta, B. Sánchez Lafuente, I. Martínez Martín, P. Cerezuela Fuentes